Turnstone Biologics’ Post

February 4th marks #WorldCancerDay, a global #awareness day to provide #education and encouragement to individuals and organizations wanting to take action to prevent and treat #cancer. Through #research and #oncology innovation, extraordinary advancements have been made in the detection, diagnostics, and treatment of cancer. Since our inception in 1997, KCR has worked with global #pharma and #biotech organizations to shed light on cancer and help deliver cutting-edge treatments to #patients in need. KCR Chief Medical Officer, Anna Baran and Principal Consultant, Dave Li recently shared their expertise in a commentary highlighting critical issues in the development of predictive biomarkers for precision #oncology. Stay tuned for the complete article. 📰 For more on World Cancer Day, visit: https://lnkd.in/eWUGREKS #KCRCRO #BostonBiotech #KCRSolutions #WCD #WorldCancerDay #oncology #CancerResearch #ClinicalTrials #ClinicalResearch

Dr. Sammy Farah, Turnstone’s President and CEO, is in #Boston today to speak at the TD Cowen Inc. 44th Annual Healthcare Conference.   Join Sammy who, following the recent monumental approval of Amtagvi, a 1st-generation TIL therapy in advanced melanoma, will present on the development of Turnstone’s next-generation “Selected TIL therapy”, and on why we believe that our differentiated selection step, designed to create a TIL product with a significantly higher proportion of tumor-reactive T cells, is the key to addressing a broad set of solid tumor indications with critical unmet need and expanding the frontiers of TIL therapy.   The webcast and replay details of the event can be accessed at Turnstone's Events page -> https://lnkd.in/g7W5n9qd #TDCowenHealthcare #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Indaptus Therapeutics’ CEO, Jeffrey Meckler, and CMO, Roger Waltzman, sat down to discuss a few key takeaways from our recent presentation at #ASCO2024. In this video, we cover: Decoy20 Strategy: Discover how our novel approach stimulates both the innate and adaptive immune systems, with a remarkable tolerability profile thanks to a significant reduction in LPS. Conference Highlights: Learn about the promising developments in CAR therapies for solid tumors and how #Decoy20 could potentially enhance these treatments. Reinforcement of Our Approach: Hear about other studies, such as Eikon Therapeutics’ EIK1001 + Pembro, that support our broad immune activation strategy. Please join us as we continue to lead the way in developing innovative new cancer treatments. #IndaptusTherapeutics #CancerResearch #Immunotherapy

Did you know that we have supported solid tumor TMB, MRD and bTMB applications with highly characterized patient-derived reference materials for several years? If not, check out this link to our page that explains these resources. #tmb #ngs #mrd

At #InVivoBiosystems, we accelerate discovery, development, and decision making with our fast and effective disease models. To further our efforts, we have partnered with BioReperia to execute cancer therapeutic efficacy testing in a timeframe of less than one week (compared to the 6+ month traditional timeframe). C. Palani Palaniappan shared his reflection on the impact our new partnership brings for cancer patients. Not only does the ZTX® platform accelerate pre-clinical discovery, but the technology has also shown to be effective with primary patient tumors, meaning the platform is providing oncologists with the ability to quickly validate therapeutic effectiveness on an individual patient before choosing a treatment to advance with. The ZTX® platform is greatly improving the quality of individualized treatment for cancer patients worldwide. #cancer #cancerresearch #oncology #biotechnology #innovation #preclinical #drugdiscovery #clinicaldevelopment #PharmaInnovation #healthcare #zebrafish

We are pleased to share our comprehensive suite of Seraseq® Tumor Monitoring Solutions, meticulously crafted to enhance and streamline your cancer monitoring workflow. Our FFPE TMB, gDNA TMB, MRD, and bTMB products are derived from tumor-matched, patient samples to ensure the accuracy and consistency needed at every stage of solid tumor treatment and recurrence monitoring. We've developed a user-friendly landing page to help you explore these solutions in detail. Click below to see how our reference materials can support your workflow: Optimize Your Cancer Monitoring Workflow with Patient-Derived Reference Materials https://hubs.ly/Q02Lt9pP0 #CancerResearch #Oncology #TumorMonitoring #Genomics #PrecisionMedicine #NGS #CancerDiagnostics #TMB #MRD #LiquidBiopsy #FFPE #GenomicData #ClinicalGenomics

🌟 Kognitic is proud to present our latest graphic: the top 20 companies spearheading Sarcoma and Bone Cancer clinical trials! 🌟 As July is World Sarcoma and Bone Cancer Awareness Month, we like to underscore the importance of continuous research and development in combating these challenging cancers. Our detailed ranking highlights the companies most active in Phase 2 and 3 trials, showcasing their commitment to advancing treatment options for sarcoma and bone cancer patients. Here's a glimpse of the top 5 leaders: 1. Amgen 2. Merck 3. Bristol-Myers Squibb (BMS) 4. Roche 5. Chia Tai Tianqing We're also excited to recognize Hansoh Pharma to the top 20, debuting with an 11 trials! Join us in celebrating these trailblazers in innovation and their relentless efforts to bring new treatments to patients faster and more effectively. Stay tuned for more updates and insights from Kognitic! #AIDrugLandscape #Sarcoma #BoneCancer #ClinicalTrials #Top20 #Kognitic #PharmaceuticalResearch #Innovation #AwarenessMonth #TPP

Lung cancer remains one of the most prevalent forms of Cancer worldwide, often diagnosed at a late stage when treatment options are more limited. This World Lung Cancer Day, by fostering a greater understanding of the disease and supporting efforts to combat it, we at COD aim to advance clinical research and drug development, and to emphasize the importance of early detection. To know more about us, write to us at bd@cod-research.com Designing Therapies for Future #WorldLungCancerDay2024 #WLCD24 #ClosetheCareGap #EveryoneDeservesAccesstoCancerCare #CODResearch

We are pleased to share our comprehensive suite of Seraseq® Tumor Monitoring Solutions, meticulously crafted to enhance and streamline your cancer monitoring workflow. Our FFPE TMB, gDNA TMB, MRD, and bTMB products are derived from tumor-matched, patient samples to ensure the accuracy and consistency needed at every stage of solid tumor treatment and recurrence monitoring. We've developed a user-friendly landing page to help you explore these solutions in detail. Click below to see how our reference materials can support your workflow: Optimize Your Cancer Monitoring Workflow with Patient-Derived Reference Materials https://hubs.ly/Q02Lt1j60 #CancerResearch #Oncology #TumorMonitoring #Genomics #PrecisionMedicine #NGS #CancerDiagnostics #TMB #MRD #LiquidBiopsy #FFPE #GenomicData #ClinicalGenomics

On Wednesday, May 15th, at 11:35 am PT (2:35 pm ET), our President and CEO, Dr. Sammy Farah, will present at the 2024 Bank of America Securities Health Care Conference. Tune in and learn more about why we believe we can expand the frontiers of TIL therapy into harder-to-treat solid tumor indications with critical unmet need, such as colorectal cancer, with Turnstone's next-generation “Selected TIL therapy”. The webcast and replay details of the event can be accessed at Turnstone's Events page -> https://lnkd.in/gB7hRYKK.   Members of Turnstone’s senior management will also be available for 1x1 meetings during the conference, and we look forward to seeing you there.   #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #CRC #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy